A Safety and Efficacy Study Evaluating CTX110 in Subjects With Relapsed or Refractory B-Cell Malignancies (CARBON)

Royal Prince Alfred Hospital, Sydney

Peter MacCallum Cancer Centre, Melbourne

Sir Charles Gairdner Hospital, Nedlands

Weill Cornell Medical College / New York Presbyterian Hospital, New York

Institut Paoli-Calmettes, Marseille

Roswell Park Cancer Insitute, Buffalo

Fox Chase Cancer Center, Philadelphia

University of Hamburg, Hamburg

University of Maryland, Baltimore

Virginia Commonwealth University Massey Cancer Center, Richmond

Duke University, Durham

Emory University Winship Cancer Institute, Atlanta

Clinica Universidad de Navarra, Pamplona

Mayo Clinic, Jacksonville

Hospital Universitario de Salamanca, Salamanca

Sarah Cannon Research Institute, Nashville

Markey Cancer Center, University of Kentucky, Lexington

University of Minnesota, Minneapolis

CHU de Lille, Lille

University of Chicago, Chicago

Washington University, St Louis

University of Kansas, Westwood

Hôpital Saint Antoine, Paris

Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas

Texas Transplant Institute, San Antonio

Cedars Sinai, Los Angeles

UCSF Medical Center, San Francisco

University Hospital Würzburg, Würzburg

Oregon Health and Science University, Portland

Swedish Cancer Institute, Seattle

Beth Israel Deaconess Medical Center, Boston

Princess Margaret Cancer Centre, Toronto

Hospital Clínic de Barcelona, Barcelona